Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction

G Mowatt,¹* L Vale,¹,² M Brazzelli,¹ R Hernandez,² A Murray,¹ N Scott,³ C Fraser,¹ L McKenzie,² H Gemmell,⁴ G Hillis⁵ and M Metcalfe⁵

¹ Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
² Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
³ Department of Public Health, Institute of Applied Health Sciences, University of Aberdeen, UK
⁴ Nuclear Medicine Physics, Department of Bio-Medical Physics and Bio-Engineering, University of Aberdeen and Grampian University Hospitals NHS Trust, UK
⁵ Cardiology Research Group, Department of Clinical Cardiology, University of Aberdeen and Grampian University Hospitals NHS Trust, UK

* Corresponding author

Executive summary

Health Technology Assessment 2004; Vol. 8: No. 30

Health Technology Assessment
NHS R&D HTA Programme
Epidemiology and background

Coronary heart disease (CHD), secondary to coronary artery disease (CAD), is the most common cause of death in the UK, resulting in over 120,000 deaths in 2001. Prevalence, which varies across the UK, increases with age; it is estimated that around 2.65 million people in the UK have CHD. Over 378,000 people received inpatient treatment for CHD in NHS hospitals in 2000–01, representing 5% of all inpatient cases in men and 2% in women.

Methods of detecting the presence and assessing the extent of CAD have become increasingly important in informing therapies aimed at reducing mortality and morbidity. Coronary angiography (CA) is considered to be the ‘gold standard’ for defining the site and severity of coronary artery lesions. CA carries a small (<0.1%) risk of mortality and routine use is inadvisable. Stress (usually treadmill or bicycle exercise) electrocardiography (ECG) is widely used for non-invasive detection of CAD owing to its availability and low cost.

Myocardial perfusion scintigraphy (MPS) may be added to the diagnostic pathway to improve detection of CAD. MPS involves the injection of a radioactive tracer followed by the imaging of its distribution within the myocardium using a gamma camera. Single photon emission computed tomography (SPECT) MPS allows the creation of tomographic images. The images following stress and at rest are compared to assess whether defects are reversible (ischaemia) or fixed (infarction) and to allow the site, extent and depth of abnormalities to be determined. This review assesses the effectiveness and cost-effectiveness of SPECT MPS for the diagnosis and management of angina and myocardial infarction (MI).

Methods

Electronic searches were conducted to identify published and unpublished studies. The following databases were searched: MEDLINE (1966 to October 2002), EMBASE (1980 to week 44, 2002), PREMEDLINE (5 November 2002), BIOSIS (1985 to December 2002), Science Citation Index (1981 to December 2002), The Cochrane Library (Issue 3, 2002), Health Management Information Consortium (1979 to 2002), Health Technology Assessment Database (October 2002) and NHS Economic Evaluation Database (October 2002). Two reviewers independently extracted data and assessed study quality.

A decision tree model (DTM) was used to model the diagnosis decision and a simple Markov model was developed for the management of patients with suspected CAD. The strategies considered in the models were (a) stress ECG, followed by SPECT if stress ECG positive, followed by CA if SPECT positive; (b) stress ECG, followed by CA if stress ECG positive; (c) SPECT, followed by CA if SPECT positive; and (d) CA (invasive test as first option).

Costs for the treatments and interventions within strategies were derived from the literature and expressed in 2001–02 pounds sterling. Quality-adjusted life-year (QALY) weights for the different Markov model states were also obtained from the literature.

Number and quality of studies and direction of evidence

Twenty-one diagnostic and 46 prognostic studies were included plus two studies comparing SPECT with ECG-gated SPECT and one study comparing SPECT with attenuation-corrected SPECT. The quality of the diagnostic studies was assessed using the quality assessment of diagnostic accuracy studies (QUADAS) tool developed by the NHS Centre for Reviews and Dissemination. Most studies gave clearly described selection criteria. In 13 studies the spectrum of patients was not considered to be representative of those who would receive the test in practice. Eight studies described the index test (SPECT) and 12 described the reference standard (CA) sufficiently to permit its replication. In 14 studies the index test was interpreted without knowledge of the reference standard, whereas in nine studies the reference standard was interpreted without knowledge of the index test. It was unclear from 16 studies whether the same clinical
data were available when test results were interpreted as would be available were the test to be used in practice. The diagnostic values of SPECT were generally higher than those of stress ECG, indicating that SPECT provided a better diagnostic performance.

The prognostic studies were all observational studies and were assessed using a checklist designed to assess the methodological quality of both randomised and non-randomised studies. The overall mean score for the prognostic studies was 18.1 (out of a possible 27). The external validity of the studies was low. The evidence from the prognostic studies suggested that SPECT provided valuable independent and incremental information to that provided by stress ECG and/or CA.

**Summary of benefits**

Of 21 diagnostic studies, 16 included patients referred for suspected or known CAD, three evaluated patients following percutaneous transluminal coronary angioplasty (PTCA), one focused on patients suspected of asymptomatic coronary disease and one evaluated patients with left bundle branch block (LBBB). Among the largest subset of studies (those assessing patients with a suspicion or a history of CAD), sensitivity values tended to be higher for SPECT than for stress ECG whereas specificity values were similar. SPECT also provided higher positive and lower negative likelihood ratios than stress ECG but heterogeneity was evident amongst studies. The subgroup of studies including patients with previous MI tended to report a better diagnostic performance for SPECT than stress ECG, but there were too few studies to assess this reliably.

Twenty-one of the 46 prognostic studies provided general prognostic information. Important factors for predicting cardiac events included the extent and size of the perfusion defect and whether it was fixed or reversible. Normal SPECT scans were associated with a benign prognosis and the option of medical rather than invasive management. Two studies comparing different testing strategies found that a strategy incorporating SPECT with selective referral to CA resulted in lower rates of normal angiograms compared with a strategy of direct referral to CA, suggesting that SPECT was better able to identify lower risk patients for whom CA might be avoided.

The remaining prognostic studies examined the use of SPECT in different patient populations. Studies in relation to gender reported that SPECT provided important, independent prediction of survival in both men and women. Studies performed in patients following MI, and after PTCA and CABG, found that SPECT imaging provided important information for predicting future cardiac events.

Two studies, one diagnostic and the other prognostic, comparing SPECT with ECG-gated SPECT, found in favour of gated SPECT. One study comparing SPECT with attenuation-corrected SPECT reported the latter to be more accurate. Although these findings seem promising it is difficult to draw conclusions from so few studies.

**Costs**

For the base-case analysis, the results for costs and QALYs for the different strategies were: strategy (a) cost of £5190 and yielding 12.473 QALYs; strategy (b) £5395, 12.481 QALYs; strategy (c) £5529, 12.497 QALYs; and strategy (d) £5929, 12.506 QALYs.

**Cost/QALY**

The systematic review of economic evaluations indicated that strategies involving SPECT were likely either to be dominant or to produce more QALYs at an acceptable cost. There was less agreement, however, about which of the strategies involving SPECT was optimal.

At the baseline prevalence of 10.5%, SPECT–CA was cost-effective whereas CA, although generating more QALYs, did so at a relatively high incremental cost per QALY (£42,225). At 30% prevalence rates, whereas SPECT–CA was cost-effective, the CA strategy produced more QALYs at a relatively low incremental cost-effectiveness ratio (£7331). At higher prevalence rates (50 and 85%), the SPECT–CA strategy was extendedly dominated by the stress ECG–CA and CA strategies. In other words, over a defined range, if some patients received stress ECG–CA with the rest receiving CA, the costs would be lower and the QALYs higher than if SPECT–CA alone was used.
Sensitivity analyses

The model suggested that, for low prevalence, the incremental cost per unit of output (true positives diagnosed, accurate diagnosis, QALY) for the move from stress ECG–SPECT–CA and from stress ECG–CA to SPECT–CA might be considered worthwhile. Even after allowing for different values for sensitivity or specificity, the least costly and least effective strategy was stress ECG–SPECT–CA. The sensitivity analysis suggested that the cost-effectiveness of SPECT–CA improved if it was assumed that SPECT results allowed for the adoption of a management strategy without recourse to CA. This would be the case if the assumption of perfect information from CA (sensitivity and specificity equal to 1) were relaxed.

Limitations of the calculations (assumptions made)

Linking diagnostic performance to long-term outcomes required a number of assumptions to be made about both the structure of the model and its parameters. Some assumptions were based on non-UK study data; it is unclear whether such data are applicable to a UK setting. Another assumption concerned the length of time over which the benefits from a diagnostic strategy might accrue. In the base-case analysis, a time period of 25 years was used, although the impact of shorter time horizons was explored in sensitivity analysis. As the time horizon reduced, the incremental cost per QALY increased (as the cost of initial diagnosis and treatment were not offset by survival and quality of life gains).

Other important issues regarding implications

Relatively poor data were available with which to consider longer term costs and consequences. The non-UK data used may not apply to a UK setting.

Notes on the generalisability of the findings

There was a considerable variability in terms of measurement of outcomes, management, setting and patient characteristics. Despite these differences the direction of evidence tended to favour SPECT in terms of test sensitivity, although these conclusions are based on a relatively small number of included studies.

All of the prognostic studies were observational studies and may be biased by unknown confounding factors. Thirty-four of the prognostic studies took place in North America and 12 were set in Europe. SPECT, in a variety of settings and patient populations, provided valuable independent and incremental information to that provided by stress ECG and/or CA. These results may not be generalisable to the UK as many studies were undertaken in countries with different healthcare systems to that of the UK.

Need for further research

Further research is needed on the effectiveness and cost-effectiveness, diagnostically and prognostically, of (a) gated and attenuation-corrected SPECT compared with standard SPECT, (b) standard SPECT compared with stress echocardiography and (c) the uncertainty surrounding the results presented in the cost-effectiveness analysis.

Publication

How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

– fax (with credit card or official purchase order)
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch Email: orders@hta.ac.uk
C/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, Havant PO9 2NP, UK Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address.

Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.
The research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’ that is being developed to improve the evidence of clinical practice throughout the NHS.

The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts. Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or designing a trial to produce new evidence where none currently exists.

Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a limited time period.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned and funded by the HTA Programme on behalf of NICE as project number 02/19/01. The authors have been wholly responsible for all data collection, analysis and interpretation and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health.

**HTA Programme Director:** Professor Tom Walley  
**Series Editors:** Dr Peter Davidson, Professor John Gabbay, Dr Chris Hyde, Dr Ruairidh Milne, Dr Rob Riemsma and Dr Ken Stein  
**Managing Editors:** Sally Bailey and Caroline Ciupek